<DOC>
	<DOCNO>NCT00769899</DOCNO>
	<brief_summary>This Phase I randomize double-blind , placebo-controlled , single centre study ass safety , tolerability pharmacokinetics AZD7325 follow single ascend dose administration healthy male Japanese volunteer .</brief_summary>
	<brief_title>AZD7325 Single Ascending Dose Study Healthy Male Japanese Subjects</brief_title>
	<detailed_description />
	<criteria>Body mass index ( BMI ) : 18 27 kg/m 2 Clinically relevant disease and/or abnormality ( past present ) Clinically relevant abnormality physical examination , vital sign , clinical chemistry , hematology urinalysis screen judge investigator Use medication herbal preparation within 14 day Study day 1 Followup Visit paracetamol ( 3 g/day ) Smoking excess 5 cigarette per day equivalent within 28 day prior first study day inability refrain smoking study confinement period</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>AZD7325</keyword>
	<keyword>Japanese Healthy Volunteers</keyword>
	<keyword>Phase I study</keyword>
	<keyword>Single Ascending Dose</keyword>
</DOC>